Citation

Kim SY, Anderson IB, Dyer JE, Barker JC, Blanc PD. Am. J. Drug Alcohol Abuse 2007; 33(3): 429-438.

Affiliation

California Poison Control System, Department of Clinical Pharmacy, University of California, San Francisco, CA 94143-1369, USA. susank@calpoison.org

Copyright

(Copyright © 2007, Informa - Taylor and Francis Group)

DOI

10.1080/00952990701312316

PMID

17613970

PMCID

PMC2257866

Abstract

INTRODUCTION: Little is known about behaviors linked to gamma hydroxybutyrate (GHB) morbidity. METHODS: We surveyed 131 GHB users, using logistic regression to test the associations between the high risk behaviors and hospital treatment for GHB (26 [20%] of subjects). RESULTS: Increased risk of GHB hospital treatment was associated with: co-ingestion of ethanol (OR 5.2; 95% CI 1.7-16), driving under the influence of GHB (OR 3.2; 95%, CI 1.3-7.8),use of GHB to treat withdrawal symptoms (OR 2.9; 95% CI 1.1-7.9), and co-ingestion of ketamine (OR 2.7; 95% CI 1.1-6.7). CONCLUSION: Targeted prevention activities could focus on selected high-risk behaviors.

Language: en